We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Investigation of the Anti-cancer Effects of the Tyrosine Kinase Inhibitor-pexidartinib on the Lung Cancer Cell Line.
- Authors
LAMA, Dilhan; YETKE, Hande İpek; DAL YÖNTEM, Fulya; HACIOSMANOĞLU ALDOĞAN, Ebru
- Abstract
Introduction: Lung cancer is the type of cancer that causes the most deaths at all ages. Tyrosine kinase inhibitors targeting driver genes are effectively used for treating adenocarcinoma. Pexidartinib is a tyrosine kinase inhibitor approved by the Food and Drug Administration in 2019 and is the first systemic agent with proven efficacy for treating tenosynovial giant cell tumors. In this study, we investigated the anti-proliferative and anti-metastatic effects of a tyrosine kinase inhibitor pexidartinib on lung adenocarcinoma cell lines. Method: In this study, BEAS-2B cell line as a healthy cell and A549 lung cancer cell line was cultured in standard conditions. The viability of cells was tested using MTT assay with pexidartinib in increasing concentrations for 24 h and 48 h. The percentages of A549 cells undergoing apoptosis were measured by AV-PI staining A-cell migration assay was performed to reveal the effect of pexidartinib on cancer cell motility. Western blotting was realized to understand the cell death mechanism with pexidartinib treatment in lung cancer cells. Results: No significant effect of treatment of pexidartinib on Beas-2B cells was observed on cell viability. However, the cell viability of lung cancer cells, A549, was decreased with treatment with pexidartinib that is even 1 ㎛ (p<0.005). Necrotic cells stained with PI were increased to pexidartinib treatment on A549 cells. There was no apoptosis induced at any concentration of pexidartinib on A549 cells. On the other hand, it was shown that pexidartinib induced necroptosis with RIP1/RIP3 expression via western blot. Conclusion: Our findings confirm the anti-cancer effects and safety of pexidartinib therapy on lung cells. However, it needs further studies to understand the related pathways of pexidartinib treatment in lung cancer.
- Subjects
UNITED States. Food &; Drug Administration; PROTEIN-tyrosine kinases; LUNG cancer; CANCER cell motility; CANCER cells; CELL lines; KINASES
- Publication
Bezmialem Science, 2023, Vol 11, pS12
- ISSN
2148-2373
- Publication type
Abstract